Why didn't LABS acknowledge with a press release the newexpanded strategic manufacturing agreement with Avicanna around end of Q2? Does this involve higher volumes on existing business and/or new products for Avicanna along with little to no clarity on LABS having acess to the SEDDS technology. Most importantly, what are the timing elements involving this? Is this a Q4 '23 plan, Q1 '24 plan, etc???